Dashboard
Manage Tickers

GILD GILEAD SCIENCES, INC.


$ 120.25 $ -0.47 (-0.39 %)    

Monday, 27-Oct-2025 19:00:04 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.19 $ 10.99 (1.78 %)
DIA $ 475.80 $ 3.14 (0.66 %)
SPY $ 685.85 $ 7.99 (1.18 %)
TLT $ 91.89 $ 0.31 (0.34 %)
GLD $ 368.19 $ -10.51 (-2.78 %)
$ na
$ 121.24
$ 120.00 x 40
$ 120.83 x 4
$ 119.50 - $ 121.58
$ 83.59 - $ 124.61
4,751,378
na
149.48B
$ 0.48
$ 23.69
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

if-you-invested-1000-in-gilead-sciences-stock-20-years-ago-you-would-have-this-much-today
If You Invested $1000 In Gilead Sciences S...
10/27/2025 14:45:17

retail-investors-top-stocks-with-earnings-this-week-sofi-apple-meta-and-more
Retail Investors' Top Stocks With Earnings...
10/27/2025 14:38:22

Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 

td-cowen-maintains-buy-on-gilead-sciences-raises-price-target-to-125
TD Cowen Maintains Buy on Gilead Sciences,...
10/23/2025 15:31:32

TD Cowen analyst Tyler Van Buren maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $115 to...

gilead-sciences-to-present-new-research-reinforcing-commitment-to-advancing-innovation-for-people-living-with-liver-disease-at-the-liver-meeting-2025
Gilead Sciences To Present New Research Re...
10/23/2025 12:05:43

- Late-Breaking Real-World Experience of People Switching from Obeticholic Acid to Livdelzi® to be Presented atThe Liver Meetin...

gilead-wins-health-canada-approval-for-new-liver-disease-drug-lyvdelzi-offering-relief-to-patients-with-limited-treatment-options
Gilead Wins Health Canada Approval For New...
10/21/2025 11:04:01

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the treatment of ...

reported-sunday-gilead-sciences-phase-3-ascent-03-study-shows-trodelvy-cut-risk-of-disease-progression-or-death-by-38-versus-chemotherapy-in-first-line-metastatic-triple-negative-breast-cancer
Reported Sunday, Gilead Sciences' Phase 3 ...
10/20/2025 07:47:49

– Late-Breaking ASCENT-03 Data Simultaneously Presented at ESMO 2025 and Published in The New England Journal of Medicine –– Wi...

reported-sunday-gilead-showcases-34-presentations-including-six-oral-sessions-across-hiv-respiratory-viruses-viral-hepatitis-pandemic-pathogens-at-idweek
Reported Sunday, Gilead Showcases 34 Prese...
10/20/2025 07:29:52

– Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo® as an Effective HIV Prevention Option A...

uk-health-agency-recommends-gsk-backed-viiv-healthcares-apretude-as-injectable-hiv-treatment
UK Health Agency Recommends GSK-Backed Vii...
10/17/2025 16:43:32

NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to dail...

mercks-new-hiv-treatment-works-as-well-as-top-drug-in-late-trials
Merck's New HIV Treatment Works As Well As...
10/15/2025 16:23:05

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase ...

gilead-presents-latest-clinical-data-on-lenacapavir-biktarvy-and-novel-long-acting-hiv-combinations-at-eacs-2025
Gilead Presents Latest Clinical Data On Le...
10/15/2025 07:56:04

 New Data Showcase Safety Profile of Twice-Yearly Lenacapavir for Pre-Exposure Prophylaxis (PrEP) with Other Medications and Re...

gilead-sciencesarcus-biosciences-investigational-cancer-drug-shows-overall-survival-of-around-27-months
Gilead Sciences/Arcus Biosciences' Investi...
10/13/2025 14:33:57

Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab combinatio...

gilead-coinbase-rocket-lab-and-a-tech-stock-on-cnbcs-final-trades
Gilead, Coinbase, Rocket Lab And A Tech St...
10/13/2025 12:32:20

On CNBC's "Halftime Report Final Trades," Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences as his final trade.

Core News & Articles
CNBC Halftime Report Final Trades: Gilead...
10/10/2025 17:01:36

breaking-down-gilead-sciences-6-analysts-share-their-views
Breaking Down Gilead Sciences: 6 Analysts ...
10/08/2025 22:01:01

citigroup-maintains-buy-on-gilead-sciences-raises-price-target-to-135
Citigroup Maintains Buy on Gilead Sciences...
10/08/2025 18:33:25

Citigroup analyst Geoff Meacham maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $125 to ...

heres-how-much-you-would-have-made-owning-gilead-sciences-stock-in-the-last-20-years
Here's How Much You Would Have Made Owning...
10/07/2025 23:45:27

gilead-says-for-q3-co-currently-expects-1704m-in-acquired-iprd-expenses-co-sees-acquired-iprd-expenses-to-represent-charge-of-about-011-to-both-gaap-and-non-gaap-eps
Gilead Says For Q3, Co Currently Expects $...
10/07/2025 20:27:23

- SEC Filing

gilead-reaches-settlement-to-block-biktarvy-generics-until-2036
Gilead Reaches Settlement To Block Biktarv...
10/06/2025 16:24:28

Gilead Sciences settled patent disputes with Lupin, Cipla, and Laurus, delaying U.S. generic entry of HIV drug Biktarvy until A...

gilead-settles-patent-disputes-to-block-generic-biktarvy-launch-in-us-until-april-2036
Gilead Settles Patent Disputes To Block Ge...
10/06/2025 12:24:50

On October 6, 2025, Gilead Sciences, Inc., a Delaware corporation ("Gilead"), announced that it has entered into settle...

gilead-sciences-entered-into-settlement-agreement-to-resolve-patent-litigation-with-lupin-cipla-and-laurus-labs-for-biktarvy
Gilead Sciences Entered Into Settlement Ag...
10/06/2025 12:22:32

https://www.sec.gov/ix?doc=/Archives/edgar/data/882095/000088209525000041/gild-20251006.htm

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION